- Felix Health plans to reduce semaglutide pricing across its weight management programs, with patients potentially saving up to 65% as generic options become available in Canada
- The company said affordability continues to impact long-term treatment adherence, with nearly 1 in 4 patients who stopped the program over the past year citing cost as the main reason
- Demand for GLP-1 therapies continues to rise, with Felix reporting ~99% YoY growth in weight loss subscribers and more than 1.1M clinical consultations to date
- Felix also highlighted the insurance gap in Canada, noting that <5% of patients are fully covered, while survey data showed willingness to use GLP-1s rose sharply when monthly costs dropped from ~$400 to ~$100
Takeaways:
Felix is positioning itself as the price‑breaker in Canada’s GLP‑1 obesity market, using cheaper semaglutide (as generics arrive) to tackle the main dropout driver and convert strong demand into longer treatment durations.
If it can bring monthly costs closer to the ~100‑dollar level that patients say they find acceptable, Felix could unlock a much larger addressable pool beyond the small share with full insurance, deepen its already 99% year‑on‑year growth in subscribers, and pressure other virtual and brick‑and‑mortar providers to follow on pricing.
Source: Globenewswire
